 |
|
|
|
 |
|||
Proxy season is almost over and the folks here at footnoted are looking forward to turning our attention over to the first quarter Qs, which have already begun to trickle in. Not that proxies aren’t lots of fun — they’re chock full of all sorts of information. But as with all SEC filings, sometimes what’s [...]
Last week, The Travelers (TRV) named veteran executive Donald J. Shepard to its board of directors, according to this 8-K filed late Friday. Snore city, right? After all, even at large companies, director changes are hard to get all that worked up about. What piqued our interest was the lack of detail in the 8-K. [...]
As most footnoted regulars know, we’ve read a lot of employment contracts and severance agreements over the years. Way too many to count, in fact. But the agreement with former Chief Operating Officer Peter Chernin that News Corp. (NWS) included in its 10-K sets new standards for saying so little. Indeed, you’d be hard pressed [...]
On Tuesday morning, Pfizer (PFE) reported 1st quarter earnings that were largely viewed as a mixed bag. But far more interesting to me, was this 8K that Pfizer filed on Monday. In the filing, the company notes that Dr. Corey S. Goodman, who ran Pfizer’s Biotherapeutics and Bioinnovation Center in South San Francisco, plans to [...]
Trying to keep up with the near-daily filings by Target (TGT) and Bill Ackman’s Pershing Square is no easy task. In two separate filings, the hedge fund has compared the company’s corporate structure to the “Third World and dictatorships” and described the board’s structure as “suboptimal”. Target, in turn, has described Ackman’s proxy contest ” [...]
RSS
